- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07937787
A Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.
The goal of this Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics following single and multiple subcutaneous administration of QLS2406-1. Part A will enroll Chinese adult participants with overweight and obesity, and Part B will enroll participants with obesity.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This study is the first-in-human (FIH) trial of QLS2406-1 injection, a randomized, double-blind, placebo-controlled Phase I clinical study consisting of two parts.
Part A is a single ascending dose (SAD) design with doses escalated sequentially per the predefined escalation scheme. Eight overweight or obese participants will be enrolled in each cohort and randomized at a 6:2 ratio to receive QLS2406-1 or placebo. Part B is a multiple ascending dose (MAD) study in obese participants. Two dosing frequencies are to be explored: once weekly (QW), and once every two weeks (Q2W). For the QW schedule, 15 obese participants will be randomized at a 12:3 ratio to receive QLS2406-1 or placebo. For the Q2W schedule, 12 participants will be randomized at a 10:2 ratio to receive QLS2406-1 or placebo.
The primary objective is to evaluate the safety and tolerability of this new long-acting quad-agonist QLS2406-1. Secondary objectives are to characterize the pharmacokinetics (PK) and to investigate if the long-acting four-receptor agonist has possible pharmacodynamic effects measured as changes in weight, waist circumference and lipid profiles.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: qian zhang, Master of Medicine
- Número de telefone: 86-0551-65997163
- E-mail: Zhangqian@ahmu.edu.com
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Part A
- Aged 18 to 55 years (inclusive) at screening, with no restriction on gender;
- At screening, female subjects have a body weight ≥50.0 kg, male subjects have a body weight ≥55.0 kg, and BMI ranges from 24.0 kg/m² to 32.0 kg/m² (inclusive);
- Subjects are in good health as comprehensively assessed by the Investigator, with no clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), abdominal ultrasonography, clinical laboratory tests, etc.;
- Female subjects have no plan for pregnancy or oocyte donation from screening to 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan for fathering a child or sperm donation from the first dose to 6 months after the last dose and agree to use at least one highly effective contraceptive method to avoid partner pregnancy.
- Subjects understand the trial procedures and potential risks before enrollment and voluntarily provide written informed consent
-
Part B
- Aged 18 to 65 years (inclusive) at screening, regardless of gender;
- BMI at screening ranges from 28.0 kg/m² to 40.0 kg/m² (inclusive);
- Female subjects have no plan for pregnancy or oocyte donation from screening through 6 months after the last dose and agree to use at least one highly effective contraceptive method. Male subjects have no plan to father a child or donate sperm from the first dose through 6 months after the last dose and agree to use at least one highly effective contraceptive method to prevent partner pregnancy;
- Subjects understand the trial procedures and potential adverse reactions prior to enrollment and voluntarily provide written informed consent;
- Body weight fluctuation within 12 weeks before screening is ≤5% (self-reported).
Exclusion Criteria:
-
Overweight or obesity known to be caused by monogenic mutation, other diseases (e.g., Cushing syndrome, hypothalamic obesity) or medications;
-
History of any severe clinical disease, or clinically significant cardiovascular, metabolic, hepatic, renal, respiratory, gastrointestinal, endocrine, immune, gynecologic, neurologic, psychiatric, musculoskeletal, hematologic disorders or malignancy within 24 weeks prior to randomization;
-
Known history of psychiatric disorders such as depression, schizophrenia, bipolar disorder, etc.;
-
Known history of gastrointestinal disease or surgery that may affect safety assessment, or planned surgery during the study;
-
Personal or family history of medullary thyroid carcinoma, C-cell hyperplasia of the thyroid, multiple endocrine neoplasia type 2; history of thyroid surgery, ¹³¹I therapy, or thyroid nodules of unknown etiology;
-
History of hypoglycemia within 24 weeks prior to randomization;
-
12-lead ECG at screening with heart rate >100 bpm or <50 bpm, second- or third-degree atrioventricular block, prolonged QTcF (>450 ms for males, >470 ms for females), or other clinically significant ECG abnormalities judged unsuitable by the Investigator; or family history of long QT syndrome or Brugada syndrome;
-
History of hypertension with ongoing antihypertensive therapy, or screening SBP ≥160 mmHg or DBP ≥90 mmHg;
-
Use of any drugs, products or non-pharmacologic therapies (other than investigational product) affecting glucose metabolism, lipid metabolism or body weight assessment within 12 weeks before screening;
-
Any screening laboratory value meeting any of the following criteria, including but not limited to:
- Serum amylase or serum lipase >1.5 × upper limit of normal (ULN);
- Fasting glucose abnormality or glycated hemoglobin (HbA1c) ≥6.5%;
- Calcitonin >20 ng/L;
- TG ≥5.65 mmol/L (500 mg/dL);
- E value ≥12.0 kPa (FibroScan) (Part B only)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A Cohort 1
SAD dose 1 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part A Cohort 2
SAD dose 2 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part A Cohort 3
SAD dose 3 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part A Cohort 4
SAD dose 4 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part A Cohort 5
SAD dose 5 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 1
MAD dose 1 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 2
MAD dose 2 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 3
MAD dose 3 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 4
MAD dose 4 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 5
MAD dose 5 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
|
Experimental: Part B Cohort 6
MAD dose 6 |
QLS2406-1 will be provided as a 50 mg/mL solution; Dose 1, a single dose, will be administered subcutaneously. Placebo will be administered as a single dose via subcutaneous injection. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 2, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution; Dose 3, a single dose, will be administered subcutaneously. Administered subcutaneously QLS2406-1 will be provided as a 50 mg/mL solution; Dose 5, a single dose, will be administered subcutaneously. QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection once weekly (QW). Placebo will be administered by subcutaneous injection once weekly (QW). QLS2406-1 will be provided as a 50 mg/mL solution, and will be administered by subcutaneous injection every 2 weeks (Q2W). Placebo will be administered by subcutaneous injection every 2 weeks (Q2W). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adverse Events (AEs)
Prazo: Baseline to Day 71
|
A summary of AEs, SAEs, and other non-serious adverse events following single subcutaneous injection of QLS2406-1 |
Baseline to Day 71
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cmax of QLS2406-1
Prazo: From baseline to the end of treatment (up to Day 71)
|
Maximum observed plasma concentration of QLS2406-1 |
From baseline to the end of treatment (up to Day 71)
|
|
AUC of QLS2406-1
Prazo: From baseline to the end of treatment (up to Day 71)
|
Area under the serum concentration-time curve (AUC) |
From baseline to the end of treatment (up to Day 71)
|
|
Tmax of QLS2406-1
Prazo: From baseline to the end of treatment (up to Day 71)
|
Evaluate the time to reach peak plasma concentration of QLS2406-1 |
From baseline to the end of treatment (up to Day 71)
|
|
Half-life of QLS2406-1
Prazo: From baseline to the end of treatment (up to Day 71)
|
Evaluate the time required for the plasma concentration of QLS2406-1 to decrease by 50% |
From baseline to the end of treatment (up to Day 71)
|
|
% Change From Baseline in Body Weight
Prazo: From baseline to the end of treatment (up to Day 71)
|
Weight |
From baseline to the end of treatment (up to Day 71)
|
|
% Change From Baseline in Fasting Lipid Concentration
Prazo: From baseline to the end of treatment (up to Day 71)
|
Fasting lipid concentration |
From baseline to the end of treatment (up to Day 71)
|
|
Incidence of Anti-drug Antibodies (ADA)
Prazo: From baseline to the end of treatment (up to Day 71)
|
Assessment of the incidence of anti-drug antibodies (ADA) developed against QLS2406-1 after dosing |
From baseline to the end of treatment (up to Day 71)
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- QLS2406-1-101
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .